[Skip to Content]
[Skip to Content Landing]
August 3, 1979

Digoxin-PrescribingMostly Good News

Author Affiliations

From the Departments of Pharmacology and Toxicology and Medicine (Drs Weintraub, Karch, and Lasagna and Mr Trabert) and the Departments of Family Medicine, Pediatrics, and Preventive Medicine and Community Health (Drs Sorensen and Becker), University of Rochester (NY) School of Medicine and Dentistry; and the School for Biomedical Education, City College of New York (Dr Morgan).

JAMA. 1979;242(5):445-448. doi:10.1001/jama.1979.03300050035023

We examined digoxin-prescribing in 47,000 prescriptions written predominantly by physicians in a large family medicine practice. Two hundred fifty-four patients received 511 digoxin prescriptions. Dose adjustments for age (16% decrease in patients older than 64 years), for renal disease (33% decrease), and for atrial fibrillation (39% increase) followed good prescribing practices. Appropriately lower loading doses were used for digitalization. However, despite continuing concern over the bioavailability of generic digoxin tablets, less than 40% of digoxin prescriptions in this study were written for the innovator's brand-name product (Lanoxin).

(JAMA 242:445-448, 1979)